Join        Login             Stock Quote

Pfizer (PFE): FDA Committee Recommends Approval Of Tofacitinib To Treat Rheumatoid Arthritis

 May 09, 2012 04:22 PM

Pfizer Inc. (NYSE:PFE) said FDA Arthritis Advisory Committee recommended approval of tofacitinib for adult patients with moderately to severely active rheumatoid arthritis.

The Arthritis Advisory Committee to the U.S. Food and Drug Administration voted 8-2 to recommend approval of the investigational agent tofacitinib.

The committee's recommendation will be considered by the FDA in its review of the New Drug Application (NDA) for tofacitinib. The FDA has provided an anticipated Prescription Drug User Fee Act (PDUFA) action date in August 2012.

If approved by the FDA, tofacitinib would be the first new oral disease-modifying antirheumatic drug (or DMARD) for rheumatoid arthritis in more than 10 years and the first rheumatoid arthritis treatment in a new class of medicines known as Janus kinase (JAK) inhibitors.

[Related -Pfizer Inc. (PFE) Q3 Earnings Preview: What To Watch?]

Rheumatoid arthritis is a chronic inflammatory autoimmune disease that typically affects the hands and feet, although any joint lined by a synovial membrane may be affected.

Rheumatoid arthritis affects about 1.3 million Americans and 23.7 million people worldwide. Although multiple treatments are available, many patients do not adequately respond, and there remains a need for additional options.

Tofacitinib has been evaluated in about 4,800 patients yielding 7,000 patient-years of exposure in a comprehensive, global clinical development program that included five pivotal Phase 3 trials and two ongoing long-term extension studies in 45 countries.

[Related -Six Stocks That Could Get An October Bump From The FDA]

Tofacitinib is currently under review for the treatment of moderately to severely active RA by several regulatory agencies around the world, including the United States, Europe and Japan.

PFE closed Wednesday's regular session up 1.13% at $22.45. The stock has been trading between $16.63 and $23.30 for the past 52 weeks.



Post Comment -- Login is required to post message
Alert for new comments:
Your email:
Your Website:

rss feed

Latest Stories

article imageHas Warren Buffett Found The Best Investment In Oil?

Shares of oil stocks plunged again as the price of West Texas Intermediate wiped out nearly half of its read on...

article imageDemand For Safe-Haven Bonds Surged Last Week

The crowd piled into investment-grade bonds last week as economic worries triggered an exodus out of risky read on...

article imageThoughts on MetLife and AIG

In some ways, this is a boring time in insurance investing.  A lot of companies seem cheap on a book and/or read on...

article imageA 2016 Recession Would Be Different

If the US or the Eurozone entered a recession this year, a few macroeconomic variables would look very read on...

Popular Articles

Daily Sector Scan
Partner Center

Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.